BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33979194)

  • 1. New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?
    Zhang B; Birer SR; Dvorkin M; Shruti J; Byers L
    Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-10. PubMed ID: 33979194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small cell lung cancer: where do we go from here?
    Byers LA; Rudin CM
    Cancer; 2015 Mar; 121(5):664-72. PubMed ID: 25336398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances in Molecular Subtyping, Characteristics and Therapeutic Strategies of 
Small Cell Lung Cancer].
    Wu Y; Zhao J; Wang M
    Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):303-309. PubMed ID: 37183645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transitioning to a Personalized Approach in Molecularly Subtyped Small-Cell Lung Cancer (SCLC).
    Grenda A; Krawczyk P; Obara A; Gajek Ł; Łomża-Łaba A; Milanowski J
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies.
    Wang H; Wu S; Li Z; Zhang C; Shang X; Zhao C; Li Z; Lin J; Guo J; Wang Z
    Cancer Sci; 2023 Feb; 114(2):665-679. PubMed ID: 36178064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What Are the Biomarkers for Immunotherapy in SCLC?
    Longo V; Catino A; Montrone M; Pizzutilo P; Annese T; Pesola F; Marech I; Cassiano S; Ribatti D; Galetta D
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations.
    Zhang C; Wang H
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188798. PubMed ID: 36096336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Small and Non-Small Cell Lung Cancer Markers in Peripheral Blood Using Cytokinesis-Blocked Micronucleus and Spectral Karyotyping Assays.
    El-Zein RA; Abdel-Rahman S; Santee KJ; Yu R; Shete S
    Cytogenet Genome Res; 2017; 152(3):122-131. PubMed ID: 28898877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential subtype-specific therapeutic approaches in small cell lung cancer.
    Horvath L; Lang C; Boettiger K; Aigner C; Dome B; Megyesfalvi Z
    Curr Opin Oncol; 2024 Jan; 36(1):51-56. PubMed ID: 37865844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Origins, genetic landscape, and emerging therapies of small cell lung cancer.
    Semenova EA; Nagel R; Berns A
    Genes Dev; 2015 Jul; 29(14):1447-62. PubMed ID: 26220992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in the treatment of small cell lung cancer.
    Hiddinga BI; Raskin J; Janssens A; Pauwels P; Van Meerbeeck JP
    Eur Respir Rev; 2021 Sep; 30(161):. PubMed ID: 34261744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SCLC-State of the Art and What Does the Future Have in Store?
    Kahnert K; Kauffmann-Guerrero D; Huber RM
    Clin Lung Cancer; 2016 Sep; 17(5):325-333. PubMed ID: 27397481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?
    Fasano R; Serratì S; Rafaschieri T; Longo V; Di Fonte R; Porcelli L; Azzariti A
    Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.
    Lai L; Meng W; Wei J; Zhang X; Tan Z; Lu Y; Hou E
    Medicine (Baltimore); 2021 Mar; 100(10):e25046. PubMed ID: 33725888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung cancer.
    Thai AA; Solomon BJ; Sequist LV; Gainor JF; Heist RS
    Lancet; 2021 Aug; 398(10299):535-554. PubMed ID: 34273294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research Progress of Immunotherapy and Prognostic Markers in Small Cell Lung Cancer].
    Wang Q; Peng W; Jiang M; Wu L
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):182-188. PubMed ID: 32102135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory.
    Kashima J; Okuma Y
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):386-395. PubMed ID: 35569741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small cells - big issues: biological implications and preclinical advancements in small cell lung cancer.
    Solta A; Ernhofer B; Boettiger K; Megyesfalvi Z; Heeke S; Hoda MA; Lang C; Aigner C; Hirsch FR; Schelch K; Döme B
    Mol Cancer; 2024 Feb; 23(1):41. PubMed ID: 38395864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung Cancer Treatment Advances in 2022.
    Abu Rous F; Singhi EK; Sridhar A; Faisal MS; Desai A
    Cancer Invest; 2023 Jan; 41(1):12-24. PubMed ID: 36036470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA-Seq profiling of circular RNAs in human small cell lung cancer.
    Zhang C; Zhang B; Yuan B; Chen C; Zhou Y; Zhang Y; Sheng Z; Sun N; Wu X
    Epigenomics; 2020 Apr; 12(8):685-700. PubMed ID: 32079426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.